

Table SIII. Individual components of the 5-D itch scale in patients with pruritus, induced by different types of targeted anticancer agents

	Chemotherapy type of patients with pruritus					Non-targeted therapy only (n = 139) Mean ± SE
	Targeted agents					
	Total Mean ± SE	EGFRIs (n = 18) Mean ± SE	VEGFRIs (n = 19) Mean ± SE	HER2Is (n = 23) Mean ± SE	Other TIs (n = 6) Mean ± SE	
5D-itch scale						
Duration	1.23 ± 0.05	1.94 ± 0.33***	1.21 ± 0.16	1.00 ± 0.00	1.33 ± 0.33	1.18 ± 0.06
Degree	2.10 ± 0.05	2.67 ± 0.24**	1.95 ± 0.12	2.22 ± 0.13	2.33 ± 0.21	2.01 ± 0.06
Direction	2.67 ± 0.08	2.83 ± 0.25	2.89 ± 0.28	2.52 ± 0.20	2.50 ± 0.34	2.65 ± 0.11
Disability						
Sleep	1.52 ± 0.07	2.06 ± 0.30*	1.37 ± 0.22	1.35 ± 0.12	1.67 ± 0.21	1.50 ± 0.08
Leisure/Social	1.81 ± 0.09	2.36 ± 0.33	1.33 ± 0.19	1.65 ± 0.24	2.33 ± 0.33	1.79 ± 0.11
Housework/Errands	1.84 ± 0.10	2.50 ± 0.40	1.58 ± 0.23	1.56 ± 0.23	2.33 ± 0.49	1.81 ± 0.12
Work/School	1.71 ± 1.11	2.56 ± 0.50	1.27 ± 0.14	1.71 ± 0.28	2.25 ± 0.75	1.63 ± 0.13
Distribution	1.51 ± 0.05	1.94 ± 0.25*	1.42 ± 0.14	1.61 ± 0.14	1.67 ± 0.42	1.45 ± 0.05

*** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$ compared to non-targeted therapy only.

EGFRIs: epidermal growth factor receptor inhibitors; HER2Is: human epidermal growth factor receptor 2 inhibitors; Other TIs: other target inhibitors; VEGFRIs: vascular endothelial growth factor receptor inhibitors; SE: standard error.